CANTON, Mass., May 20 /PRNewswire-FirstCall/ -- Avitar, Inc. (Amex: - ) today announced that Richard R. Anderson, PhD. has been appointed Vice President of Research & Development. Dr Anderson was a co-founder of BioSite, a point-of-care diagnostic company that markets Triage, a drugs-of-abuse, urine point-of-collection test as well as other diagnostic point-of-care tests. Triage is the leading drugs-of-abuse point-of-care test in the clinical market. He was also a founding member of NOTA, the National On-site Testing Association. Recently he was Vice President of Product Development for Genicon Services, a life sciences company.
Dr. Anderson fills the vacancy created when Dr. Carl Good retired from Avitar. Dr. Good continues as a senior advisor to the Company.
"We are thrilled to have a scientist of Rick's caliber join our senior management team," said Peter P. Phildius, Chairman and CEO. "His background positions us well to further advance our technical capability in the drugs-of- abuse testing market as well as the clinical market. We also want to thank Dr. Good for his enormous contribution to Avitar and look forward to having both Carl's advice as well as Rick's full-time involvement to keep Avitar on the forefront of saliva based instant diagnostics.
Avitar, Inc. develops, manufactures and markets innovative and proprietary products in the oral fluid diagnostic market, disease and clinical testing market, and customized polyurethane applications used in the wound dressing industry. Oral fluid diagnostics includes the estimated $1.5 billion drugs-of- abuse testing market, which encompasses the corporate workplace and criminal justice markets. Avitar's products include ORALscreen(TM), the world's first non-invasive, rapid, onsite oral fluid test for drugs-of-abuse. Additionally, Avitar manufactures and markets HYDRASORB(TM) an absorbent topical dressing for moderate to heavy exudating wounds. In the estimated $25 billion in vitro diagnostics market, Avitar is developing diagnostic strategies for disease and clinical testing. Some examples include influenza, diabetes and pregnancy. For more information, see Avitar's website at avitarinc.com.
Safe Harbor Statement. This release contains forward looking statements that are subject to risks and uncertainties including the development and marketing of new applications and other risks that are detailed from time to time in the Company's filings with the Securities and Exchange Commission. In view of such risks and uncertainties, the Company's actual results could differ materially from those anticipated in such forward looking statements